Shulov Institute for Science Ltd. (S.I.S)
|Company:||Shulov Institute for Science Ltd. (S.I.S)|
|Tel:||+972 8 9314114|
|Fax:||+972 8 9314114|
|Technology Classification:||Drugs Development|
|Main Business Activity:||A novel bio-pharmaceutical (anti-viral) substance formulated as a cream for topical application directly on the skin to treat various skin disorders, such as HSV1 induced clinical symptoms.|
Company Profile, Products & Technologies, Target Market:
S.I.S was founded in 1985 by Mr. Aviv Marx and Prof. Aharon Shulov who was Professor of Zoology at the world-famous Hebrew University of Jerusalem. The company is focused in development of human therapeutics derived from snake venom. The company has more than 25 years of R&D research experience in the area of chronic pain. During this period the company has isolated from the total mixture of the viper snake venom a novel non-toxic active analgesic tetra peptide. These pre-clinical results were the basis for the current idea of formulating a solution for the herpes virus.
Brief description of proposed R&D project:
The purpose of the current co-operation is to develop a novel product, a novel synthetic tetra peptide formulated as a cream for topical application on the skin to treat various skin disorders, such as Herpes Simplex Virus 1 (HSV1) induced clinical symptoms. Prepare an IND file for Phase I clinical study based on the accumulated safety toxicology data, submit the file and perform the Phase I study.
Topical application of the cream twice a day eliminates pain within few minutes and prevents swelling and lesion formation within 36 hours in a mouse model that mimics the clinical symptoms induced by HSV1 infection.
Desired Profile of R&D Partner and its role in the proposed project:
The Israeli company motivation is to co-operate with an experienced company who can meet the safety tests, thus an IND file will be submitted in 24 months to the regulatory authority. This company should have the required labs for such an R&D activity.